May 28, 2017
Recommended Topic Related To:


"On December 19, the U.S. Food and Drug Administration approved Rapivab (peramivir) to treat influenza infection in adults.

Influenza, commonly known as the flu, is a contagious respiratory illness caused by influenza viruses. Flu infections"...




  • Inform the vaccine recipient or guardian of the potential benefits and risks of immunization with AFLURIA.
  • Inform the vaccine recipient or guardian that AFLURIA is an inactivated vaccine that cannot cause influenza but stimulates the immune system to produce antibodies that protect against influenza, and that the full effect of the vaccine is generally achieved approximately 3 weeks after vaccination.
  • Instruct the vaccine recipient or guardian to report any severe or unusual adverse reactions to their healthcare provider.
  • Encourage women who receive AFLURIA while pregnant to participate in the exposure and surveillance study. Pregnant women can contact the pregnancy study center by calling 1-877-311-8972 or visiting the website
  • Provide the vaccine recipient or guardian with Vaccine Information Statements which are required by the National Childhood Vaccine Injury Act of 1986 to be given prior to immunization. These materials are available free of charge at the Centers for Disease Control and Prevention (CDC) website (
  • Instruct the vaccine recipient or guardian that annual revaccination is recommended.

Last reviewed on RxList: 10/20/2016
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.